2 x 2 x 2 WEEK DOSING REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 3.75 % IMIQUIMOD,申请号US201113181499-传众专利搜索

2 x 2 x 2 WEEK DOSING REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 3.75 % IMIQUIMOD

申请公布号：US2011257218(A1)

申请号：US201113181499

申请日期：2011.07.12

申请公布日期：2011.10.20

申请人：

GRACEWAY PHARMACEUTICALS, LLC

发明人：NORDSIEK MICHAEL T.;LEVY SHARON F.;LEE JAMES H.;KULP JAMES H.;BALAJI KODUMUDI S.;MENG TZE-CHIANG;WU JASON J.;BAHM VALYN S.;BABILON ROBERT

分类号：A61K31/4745;A61P17/00;A61P17/12

主分类号：A61K31/4745

摘要：Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.